Rapamycin attenuated cardiac hypertrophy induced by isoproterenol and maintained energy homeostasis via inhibiting NF- B activation

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Chen, Xi ^a   Zeng, Siyu ^a   Zou, Jian ^b   Chen, Yanfang ^c   Yue, Zhongbao ^a   Gao, Ying ^a   Zhang, Luankun ^a   Cao, Weiwei ^a   Liu, Peiqing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b CHENGDU FIFTH PEOPLE S HOSPITAL   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE 1BETA; CARNITINE PALMITOYLTRANSFERASE 2; CARNITINE PALMITOYLTRANSFERASE I; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 2; ISOPRENALINE; LONG CHAIN ACYL COENZYME A DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN; MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; RAPAMYCIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; ENERGY HOMEOSTASIS; ENZYME INACTIVATION; FATTY ACID METABOLISM; GENE EXPRESSION; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HOMEOSTASIS; INFLAMMATION; MALE; MITOCHONDRION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; TREATMENT DURATION; UPREGULATION; ANIMAL; CARDIOMEGALY; CELL CULTURE; CHEMICALLY INDUCED; DRUG EFFECTS; ENERGY METABOLISM; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CARDIOMEGALY; CELLS, CULTURED; ENERGY METABOLISM; HOMEOSTASIS; ISOPROTERENOL; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; NF-KAPPA B; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; SIROLIMUS;

EID: 84904111086     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/868753     Document Type: Article

References (43)

1. Lorell B. H., Carabello B. A., Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 2000 102 4 470 479 2-s2.0-0034713820 (Pubitemid 30490688)
2. Okin P. M., Hille D. A., Kjeldsen S. E., Dahlof B., Devereux R. B., Persistence of left ventricular hypertrophy is associated with increased cardiovascular morbidity and mortality in hypertensive patients with lower achieved systolic pressure during antihypertensive treatment. Blood Pressure 2013 23 2 71 80 10.3109/08037051.2013.791414
3. Neubauer S., The failing heart-an engine out of fuel. The New England Journal of Medicine 2007 356 11 1140 1151 2-s2.0-33947239659 10.1056/NEJMra063052 (Pubitemid 46425598)
4. Lopaschuk G. D., Ussher J. R., Folmes C. D. L., Jaswal J. S., Stanley W. C., Myocardial fatty acid metabolism in health and disease. Physiological Reviews 2010 90 1 207 258 2-s2.0-74949133862 10.1152/physrev.00015.2009
5. Terman A., Brunk U. T., Myocyte aging and mitochondrial turnover. Experimental Gerontology 2004 39 5 701 705 2-s2.0-2342457124 10.1016/j.exger.2004.01.005 (Pubitemid 38586810)
6. Rosca M. G., Tandler B., Hoppel C. L., Mitochondria in cardiac hypertrophy and heart failure. Journal of Molecular and Cellular Cardiology 2013 55 1 31 41 2-s2.0-84872676487 10.1016/j.yjmcc.2012.09.002
7. Meredith I. T., Eisenhofer G., Lambert G. W., Dewar E. M., Jennings G. L., Esler M. D., Cardiac sympathetic nervous activity in congestive heart failure: evidence for increased neuronal norepinephrine release and preserved neuronal uptake. Circulation 1993 88 1 136 145 2-s2.0-0027229631 (Pubitemid 23195442)
8. Bisognano J. D., Weinberger H. D., Bohlmeyer T. J., Pende A., Raynolds M. V., Sastravaha A., Roden R., Asano K., Blaxall B. C., Wu S. C., Communal C., Singh K., Colucci W., Bristow M. R., Port D. J., Myocardial-directed overexpression of the human β 1-adrenergic receptor in transgenic mice. Journal of Molecular and Cellular Cardiology 2000 32 5 817 830 2-s2.0-0033837640 10.1006/jmcc.2000.1123 (Pubitemid 30658918)
9. Rivard K., Paradis P., Nemer M., Fiset C., Cardiac-specific overexpression of the human type 1 angiotensin II receptor causes delayed repolarization. Cardiovascular Research 2008 78 1 53 62 2-s2.0-41149107344 10.1093/cvr/cvn020 (Pubitemid 351430969)
10. Shimizu M., Sasaki H., Sanjo J., Ogawa K., Mizokami T., Yagi T., Kato H., Hamaya K., Namiki A., Isogai Y., Effect of captopril on isoproterenol-induced cardiac hypertrophy and polyamine contents. Japanese Circulation Journal 1992 56 11 1130 1137 2-s2.0-0027097924 (Pubitemid 23014861)
11. Saunders R. N., Metcalfe M. S., Nicholson M. L., Rapamycin in transplantation: a review of the evidence. Kidney International 2001 59 1 3 16 2-s2.0-0035165578 10.1046/j.1523-1755.2001.00460.x (Pubitemid 32055209)
12. Kanamori H., Takemura G., Goto K., Maruyama R., Tsujimoto A., Ogino A., Takeyama T., Kawaguchi T., Watanabe T., Fujiwara T., Fujiwara H., Seishima M., Minatoguchi S., The role of autophagy emerging in postinfarction cardiac remodelling. Cardiovascular Research 2011 91 2 330 339 2-s2.0-79959967420 10.1093/cvr/cvr073
13. Paoletti E., Amidone M., Cassottana P., Gherzi M., Marsano L., Cannella G., Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial. American Journal of Kidney Diseases 2008 52 2 324 330 2-s2.0-47349128927 10.1053/j.ajkd.2008.04.018 (Pubitemid 351997440)
14. Oudit G. Y., Crackower M. A., Eriksson U., Sarao R., Kozieradzki I., Sasaki T., Irie-Sasaki J., Gidrewicz D., Rybin V. O., Wada T., Steinberg S. F., Backx P. H., Penninger J. M., Phosphoinositide 3-kinase γ -deficient mice are protected from isoproterenol-induced heart failure. Circulation 2003 108 17 2147 2152 2-s2.0-0242381308 10.1161/01.CIR.0000091403.62293.2B (Pubitemid 37337593)
15. Zou J., Le K., Xu S., Chen J., Liu Z., Chao X., Geng B., Luo J., Zeng S., Ye J., Liu P., Fenofibrate ameliorates cardiac hypertrophy by activation of peroxisome proliferator-activated receptor- α partly via preventing p65-NF B binding to NFATc4. Molecular and Cellular Endocrinology 2013 370 1-2 103 112 2-s2.0-84876358846 10.1016/j.mce.2013.03.006
16. Oriyanhan W., Tsuneyoshi H., Nishina T., Matsuoka S., Ikeda T., Komeda M., Determination of optimal duration of mechanical unloading for failing hearts to achieve bridge to recovery in a rat heterotopic heart transplantation model. Journal of Heart and Lung Transplantation 2007 26 1 16 23 2-s2.0-33846240473 10.1016/j.healun.2006.10.016 (Pubitemid 46096745)
17. Singh R., Kaushik S., Wang Y., Xiang Y., Novak I., Komatsu M., Tanaka K., Cuervo A. M., Czaja M. J., Autophagy regulates lipid metabolism. Nature 2009 458 7242 1131 1135 2-s2.0-65949095803 10.1038/nature07976
18. Bugger H., Schwarzer M., Chen D., Schrepper A., Amorim P. A., Schoepe M., Nguyen T. D., Mohr F. W., Khalimonchuk O., Weimer B. C., Doenst T., Proteomic remodelling of mitochondrial oxidative pathways in pressure overload-induced heart failure. Cardiovascular Research 2010 85 2 376 384 2-s2.0-72949110566 10.1093/cvr/cvp344
19. Fu J. J., Gao H., Pi R. B., Liu P. Q., An optimized protocol for culture of cardiomyocyte from neonatal rat. Cytotechnology 2005 49 2-3 109 116 2-s2.0-33745511754 10.1007/s10616-006-6334-6 (Pubitemid 43961440)
20. Li Y., Zhang H., Liao W., Song Y., Ma X., Chen C., Lu Z., Li Z., Zhang Y., Transactivated EGFR mediates α 1-AR-induced STAT3 activation and cardiac hypertrophy. American Journal of Physiology: Heart and Circulatory Physiology 2011 301 5 H1941 H1951 2-s2.0-80355134501 10.1152/ajpheart.00338.2011
21. Nakagawa Y., Kuwahara K., Takemura G., Akao M., Kato M., Arai Y., Takano M., Harada M., Murakami M., Nakanishi M., Usami S., Yasuno S., Kinoshita H., Fujiwara M., Ueshima K., Nakao K., P300 plays a critical role in maintaining cardiac mitochondrial function and cell survival in postnatal hearts. Circulation Research 2009 105 8 746 754 2-s2.0-70350129460 10.1161/CIRCRESAHA. 109.206037
22. Molkentin J. D., Lu J.-R., Antos C. L., Markham B., Richardson J., Robbins J., Grant S. R., Olson E. N., A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998 93 2 215 228 2-s2.0-0032540267 10.1016/S0092-8674(00)81573-1 (Pubitemid 28180855)
23. Neufeld T. P., Contribution of Atg1-dependent autophagy to TOR-mediated cell growth and survival. Autophagy 2007 3 5 477 479 2-s2.0-34548102440 (Pubitemid 47293732)
24. Terman A., Kurz T., Navratil M., Arriaga E. A., Brunk U. T., Mitochondrial Turnover and aging of long-lived postmitotic cells: the mitochondrial-lysosomal axis theory of aging. Antioxidants and Redox Signaling 2010 12 4 503 535 2-s2.0-75349112375 10.1089/ars.2009.2598
25. Fritah A., Steel J. H., Nichol D., Parker N., Williams S., Price A., Strauss L., Ryder T. A., Mobberley M. A., Poutanen M., Parker M., White R., Elevated expression of the metabolic regulator receptor-interacting protein 140 results in cardiac hypertrophy and impaired cardiac function. Cardiovascular Research 2010 86 3 443 451 2-s2.0-77952391461 10.1093/cvr/cvp418
26. Vallabhapurapu S., Karin M., Regulation and function of NF- B transcription factors in the immune system. Annual Review of Immunology 2009 27 693 733 2-s2.0-67650724069 10.1146/annurev.immunol.021908.132641
27. Planavila A., Laguna J. C., Vázquez-Carrera M., Nuclear factor- B activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy. The Journal of Biological Chemistry 2005 280 17 17464 17471 2-s2.0-20444466460 10.1074/jbc.M414220200 (Pubitemid 41389218)
28. Sawyers C. L., Will mTOR inhibitors make it as cancer drugs? Cancer Cell 2003 4 5 343 348 2-s2.0-0344063370 10.1016/S1535-6108(03)00275-7 (Pubitemid 37491095)
29. Dan H. C., Cooper M. J., Cogswell P. C., Duncan J. A., Ting J. P.-Y., Baldwin A. S., Akt-dependent regulation of NF- B is controlled by mTOR and Raptor in association with IKK. Genes and Development 2008 22 11 1490 1500 2-s2.0-44849117768 10.1101/gad.1662308 (Pubitemid 351793083)
30. Tracey K. J., Lowry S. F., Cerami A., The pathophysiologic role of cachectin/TNF in septic shock and cachexia. Annales de l'Institut Pasteur Immunology 1988 139 3 311 317 2-s2.0-0023904547
31. Martina J. A., Chen Y., Gucek M., Puertollano R., MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB. Autophagy 2012 8 6 903 914 2-s2.0-84864874958 10.4161/auto.19653
32. Settembre C., de Cegli R., Mansueto G., Saha P. K., Vetrini F., Visvikis O., Huynh T., Carissimo A., Palmer D., Klisch T. J., Wollenberg A. C., di Bernardo D., Chan L., Irazoqui J. E., Ballabio A., TFEB controls cellular lipid metabolism through a starvation-induced autoregulatory loop. Nature Cell Biology 2013 15 8 647 658 2-s2.0-84881465458 10.1038/ncb2814
33. Finck B. N., Kelly D. P., Peroxisome proliferator-activated receptor γ coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease. Circulation 2007 115 19 2540 2548 2-s2.0-34248589911 10.1161/CIRCULATIONAHA.107.670588 (Pubitemid 46763228)
34. Watanabe K., Fujii H., Takahashi T., Kodama M., Aizawa Y., Ohta Y., Ono T., Hasegawa G., Naito M., Nakajima T., Kamijo Y., Gonzalez F. J., Aoyama T., Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor α associated with age-dependent cardiac toxicity. The Journal of Biological Chemistry 2000 275 29 22293 22299 2-s2.0-0034698051 10.1074/jbc.M000248200 (Pubitemid 30621813)
35. Martín M. A., Gómez M. A., Guillén F., Börnstein B., Campos Y., Rubio J. C., De La Calzada C. S., Arenas J., Myocardial carnitine and carnitine palmitoyltransferase deficiencies in patients with severe heart failure. Biochimica et Biophysica Acta 2000 1502 3 330 336 2-s2.0-0034670070 10.1016/S0925-4439(00)00061-2
36. Palomer X., Álvarez-Guardia D., Rodríguez-Calvo R., Coll T., Laguna J. C., Davidson M. M., Chan T. O., Feldman A. M., Vázquez-Carrera M., TNF- α reduces PGC-1 α expression through NF- B and p38 MAPK leading to increased glucose oxidation in a human cardiac cell model. Cardiovascular Research 2009 81 4 703 712 2-s2.0-60149110303 10.1093/cvr/cvn327
37. Shioi T., McMullen J. R., Tarnavski O., Converso K., Sherwood M. C., Manning W. J., Izumo S., Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 2003 107 12 1664 1670 2-s2.0-0037382861 10.1161/01.CIR.0000057979.36322.88 (Pubitemid 36397337)
38. McMullen J. R., Sherwood M. C., Tarnavski O., Zhang L., Dorfman A. L., Shioi T., Izumo S., Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 2004 109 24 3050 3055 2-s2.0-3042608187 10.1161/01.CIR.0000130641.08705.45 (Pubitemid 38808328)
39. Sadoshima J., Izumo S., Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro: potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. Circulation Research 1995 77 6 1040 1052 2-s2.0-0028847159
40. Jaffré F., Callebert J., Sarre A., Etienne N., Nebigil C. G., Launay J.-M., Maroteaux L., Monassier L., Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1 β and tumor necrosis factor- α cytokine production by ventricular fibroblasts. Circulation 2004 110 8 969 974 2-s2.0-4344679310 10.1161/01.CIR.0000139856.20505.57 (Pubitemid 39128622)
41. Matkovich S. J., Diwan A., Klanke J. L., Hammer D. J., Marreez Y., Odley A. M., Brunskill E. W., Koch W. J., Schwartz R. J., Dorn G. W. II, Cardiac-specific ablation of G-protein receptor kinase 2 redefines its roles in heart development and β -adrenergic signaling. Circulation Research 2006 99 9 996 1003 2-s2.0-33750428974 10.1161/01.RES.0000247932.71270.2c (Pubitemid 44657803)
42. Drews O., Tsukamoto O., Liem D., Streicher J., Wang Y., Ping P., Differential regulation of proteasome function in isoproterenol-induced cardiac hypertrophy. Circulation Research 2010 107 9 1094 1101 2-s2.0-78349311576 10.1161/CIRCRESAHA.110.222364
43. Fujishima Y., Nishiumi S., Masuda A., Inoue J., Nguyen N. M. T., Irino Y., Komatsu M., Tanaka K., Kutsumi H., Azuma T., Yoshida M., Autophagy in the intestinal epithelium reduces endotoxin-induced inflammatory responses by inhibiting NF- B activation. Archives of Biochemistry and Biophysics 2011 506 2 223 235 2-s2.0-79151474603 10.1016/j.abb.2010.12.009